Results 31 to 40 of about 5,353 (192)

Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines

Iranian Journal of Allergy, Asthma and Immunology, 2019
Acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) are common acute leukemia in adults and children, respectively. In these malignancies, chemotherapy is the main treatment strategy that fails in many cases and is usually associated with ...
Mahdi Habibi-Anbouhi, Zahra Kafi, Leila Ghazizadeh, Shabnam Kharazi, Mahdi Behdani, Fatemeh Faraji, Mohammadi Ali Shokrgozar   +6 more
doaj   +1 more source

Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm

Frontiers in Oncology, 2022
Mature plasmacytoid dendritic cell proliferations (MPDCPs) are clonal, non-malignant pDC proliferations that have been reported to occur in association with myeloid neoplasms such as CMML, AML (pDC-AML), and, rarely, MDS or MPNs. Here we report the first
Fei Fei, Michaela Liedtke, Oscar Silva
doaj   +1 more source

AML-230 Predictive Value of CD34-Positive versus CD34-Negative Leukemic Stem Cells on Survival Outcome in Acute Myeloid Leukemia

, 2022
Context: Leukemic stem cells (LSCs) have emerged as a potential factor contributing to an overall dismal outcome in acute myeloid leukemia (AML).
Rai, Sandeep, Smeeta Gajendra, Nupur Das, Gupta, Ritu, Panda, Devasis, Bakhshi, Sameer, Gajendra, Smeeta, Lalit Kumar, Kumar, Lalit, Saroj Singh, Sameer Bakhshi, Sahoo, Ranjit K, Devasis Panda, Ritu Gupta, Singh, Saroj, Ranjit K Sahoo, Sandeep Rai, Das, Nupur, Sharma, Atul, Vijay K Prajapati, Prajapati, Vijay K, Atul Sharma   +21 more
core   +1 more source

Supplementary Table S2 from Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax

, 2023
Clinical, molecular, and cytogenetic characteristics of patient samples (CD34+CD38-CD123+ population) exposed to ABT-199 ± INK ...
Mohamed Rahmani (15053467), Toshihisa Satta (15053446), Liang Zhou (15053470), Lin Li (15053449), Sri Lakshmi Chalasani (15053452), Maciej Kmieciak (15053464), Xiaoyan Hu (15053455), Kanika Sharma (15053461), Steven Grant (15013589), Jewel Nkwocha (15053458)   +9 more
core   +2 more sources

Immunology of bone marrow CD34 subsets and clonal hematopoiesis of indeterminate potential in amyotrophic lateral sclerosis [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction. Recent advances in pathogenesis of neurodegenerative diseases have shown that inflammation is a key factor of progression. Methods. The amyotrophic lateral sclerosis (ALS) group included 10 patients [mean age 55.1 ± 3.1 years (CI 95%: 48–62.
Dolgopolov Igor S., Grivtsova Ludmila Y., Kovalenko Nikolai I., Shatalov Petr A., Bryukhovetsky Andrey S., Rykov Maxim Yu.   +5 more
doaj   +1 more source

ABSENT CD33 IN AML PATIENT MIMICS MRD POSITIVE: A SINGLE CASE REPORT

Hematology, Transfusion and Cell Therapy, 2021
Background: Diagnosis and treatment of acute myeloid leukemia (AML) remains difficult to this day, cure rates remain low and measurable residual disease (MRD) assessment is still challenging.
LO Marani, AFO Costa, FB Silva, MIA Madeira, PS Scheucher, JL Schiavinato, ASG Lima, KBB Pagnano, BK Duarte, S Freeman, F Traina, EM Rego, LL Figueiredo-Pontes   +12 more
doaj   +1 more source

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Haematologica, 2012
Background CD33 is a well-known stem cell target in acute myeloid leukemia. So far, however, little is known about expression of CD33 on leukemic stem cells in chronic leukemias.Design and Methods We analyzed expression of CD33 in leukemic progenitors in
Harald Herrmann, Sabine Cerny-Reiterer, Karoline V. Gleixner, Katharina Blatt, Susanne Herndlhofer, Werner Rabitsch, Eva Jäger, Gerlinde Mitterbauer-Hohendanner, Berthold Streubel, Edgar Selzer, Ilse Schwarzinger, Wolfgang R. Sperr, Peter Valent   +12 more
doaj   +1 more source

The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia

Haematologica, 2020
Leukemic stem cells are multipotent, self-renewing, highly proliferative cells that can withstand drug treatments. Although currently available treatments potentially destroy blast cells, they fail to eradicate leukemic progenitor cells completely ...
Charyguly Annageldiyev, Krishne Gowda, Trupti Patel, Priyanjali Bhattacharya, Su-Fern Tan, Soumya Iyer, Dhimant Desai, Sinisa Dovat, David J. Feith, Thomas P. Loughran, Shantu Amin, David Claxton, Arati Sharma   +12 more
doaj   +1 more source

DISTINCTION BETWEEN ACUTE MYELOID LEUKAEMIA WITH MYELODYSPLASIA-RELATED CHANGES AND MIXED-PHENOTYPE ACUTE LEUKAEMIA: A DIAGNOSTIC CHALLENGE

Hematology, Transfusion and Cell Therapy, 2021
The revised 4th edition of the World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues is based on clinical, morphological, immunophenotypic and genetic features.
NA Marcondes, BM Spindler, MS Vieira, LD Olivo, FB Fernandes   +4 more
doaj   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source